Global Urea Cycle Disorder Market Size - Forecasts to 2028 Brooklyn, New York, Feb. 27, 2023 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Urea Cycle Disorder Market is estimated to be valued...

Translate Bio Presents Preclinical Data Supporting MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting -- MRT5201 was efficiently delivered to the liver of a mouse model of OTC deficiency -- -- Preclinical data demonstrated a single IV dose of MRT5201 was sufficient to protect against hyperammonemia...

Horizon Pharma plc Submits Supplemental New Drug Application for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to Expand Age Range to Include Newborns DUBLIN, Ireland, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that it has submitted a supplemental New Drug Application (sNDA) with the U.S. Food and Drug...

Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to People with Urea Cycle Disorders Two Months of Age and Older DUBLIN, Ireland, May 01, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...

Horizon Pharma plc to Present Data on RAVICTI® (glycerol phenylbutyrate) Oral Liquid for Urea Cycle Disorder Patients Aged Two Months to Two Years DUBLIN, Ireland, March 22, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...